Observational StudyNCT07807943
Prospective Observational Study Of Geniculate Artery Embolization For Symptomatic Knee Osteoarthritis In A Cancer Population
An observational study of Observational Study and Geniculate Artery, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To explore associations with demographics/clinical factors; assess trajectories via annual follow-up; evaluate healthcare utilization and barriers; oversample >10-year survivors. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Observational Study, Geniculate Artery, Embolization
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Aug 2026to 30 Jun 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: UT MD Anderson Cancer Center
Who may be able to join
- Age ≥40 years with no upper age restriction, provided performance status permits procedural candidacy
- Symptomatic mild-to-severe knee osteoarthritis (Kellgren-Lawrence grade 2-4) on radiographs within 6 months of enrollment
- Chronic knee pain (NRS ≥4/10) for ≥3 months despite conservative treatment including steroid injections, physical therapy, and/or analgesic medications
- Inadequate candidate for or refusal of surgical intervention (e.g., total knee arthroplasty) due to cancer-related comorbidities, ongoing treatment, or participants preference
- Active cancer diagnosis (solid tumor or hematologic malignancy) confirmed at MD Anderson Cancer Center
Who cannot join
- Active joint infection or suspected septic arthritis
- Life expectancy <6 months
- Prior knee arthroplasty in the index knee
- Coagulopathy or contraindications to angiography
- GFR <30 mL/min/1.73m²
- Peripheral artery disease with stenosis or occlusion of lower extremity vasculature (relative contraindication per SIR standards, given geniculate artery collateral perfusion role)
Show all 9Show fewer
- Radiographically normal knee joint (KL grade 0-1) - alternative etiologies should be sought
- Known active autoimmune/inflammatory arthropathy (e.g., rheumatoid arthritis, psoriatic arthritis)
- Any medical condition or clinical abnormality that, per investigator judgment, precludes safe participation in and completion of the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UT MD Anderson Cancer Center
Houston, Texas, 77044
Nicolas J Cardenas, MD, 713-794-4404, NJCardenas@mdanderson.org
Cardenas J Nicolas, MD
About this study
To explore associations with demographics/clinical factors; assess trajectories via annual follow-up; evaluate healthcare utilization and barriers; oversample >10-year survivors.
Read the detailed description
Primary Objective To characterize the change in knee pain and functional disability following standard-of-care GAE in cancer participants with symptomatic knee osteoarthritis, as measured by mean change in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline to 12 months
- Being tested
- SOC (Standard of care)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SOC (Standard of care)Other
Patients scheduled for standard of care
What is being measured
The primary outcome is the main question the study is designed to answer.
Numeric Rating Scale Questionnaire
Measured: Through study completion; an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2026
- Study start26 Aug 2026
- Primary completion30 May 2028 (estimated)
- Study completion30 Jun 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Observational StudyStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nicolas J Cardenas, MD, Principal investigator, UT MD Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07807943
- Sponsor's protocol ID
- 2026-0111
- Other IDs
- NCI-2026-06646
- Status last verified
- Sep 2026
- First submitted
- 2 Sep 2026
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Observational Study Of Geniculate Artery Embolization For Symptomatic Knee Osteoarthritis In A Cancer Population
- ClinicalTrials.gov ID
- NCT07807943
- Acronym / sponsor ID
- 2026-0111
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 26 Aug 2026 (actual)
- Primary completion
- 30 May 2028 (estimated)
- Study completion
- 30 Jun 2030 (estimated)
- First posted
- 8 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To explore associations with demographics/clinical factors; assess trajectories via annual follow-up; evaluate healthcare utilization and barriers; oversample >10-year survivors.
Detailed description
Primary Objective To characterize the change in knee pain and functional disability following standard-of-care GAE in cancer participants with symptomatic knee osteoarthritis, as measured by mean change in the total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline to 12 months
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- UT MD Anderson Cancer Center
Key inclusion criteria (5 listed)
- Age ≥40 years with no upper age restriction, provided performance status permits procedural candidacy
- Symptomatic mild-to-severe knee osteoarthritis (Kellgren-Lawrence grade 2-4) on radiographs within 6 months of enrollment
- Chronic knee pain (NRS ≥4/10) for ≥3 months despite conservative treatment including steroid injections, physical therapy, and/or analgesic medications
- Inadequate candidate for or refusal of surgical intervention (e.g., total knee arthroplasty) due to cancer-related comorbidities, ongoing treatment, or participants preference
- Active cancer diagnosis (solid tumor or hematologic malignancy) confirmed at MD Anderson Cancer Center
Key exclusion criteria (9 listed)
- Active joint infection or suspected septic arthritis
- Life expectancy <6 months
- Prior knee arthroplasty in the index knee
- Coagulopathy or contraindications to angiography
- GFR <30 mL/min/1.73m²
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SOC (Standard of care)Patients scheduled for standard of care | Other | – |
Primary outcome
Numeric Rating Scale Questionnaire
Time frame: Through study completion; an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- UT MD Anderson Cancer CenterLink provided by the sponsor.
Related trials for Observational Study
Not yet recruitingObservational study
Longitudinal Registry of Difficult-to-Treat Inflammatory Bowel Disease
Inflammatory Bowel Diseases (IBD), Crohn Disease
RecruitingObservational study
Prospective Observational Cohort Study for Predicting Unruptured Intracranial Aneurysm Rupture Risk Using Blood Pressure Variability and 3D Structural Evolution
Unruptured Intracranial Aneurysm, Intracranial Aneurysm Rupture
Active, not recruitingObservational study
A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
Muscular Atrophy, Spinal
Active, not recruitingObservational study
A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients
Atypical Hemolytic Uremic Syndrome(aHUS)
Not yet recruitingObservational study
Intra-Abdominal Pressure, Respiratory Mechanics, and Ventilator Liberation After Emergency Major Laparotomy
Intra-Abdominal Hypertension, Respiratory Mechanics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nicolas J Cardenas, MD principal investigator
UT MD Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Observational Study and Geniculate Artery, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nicolas J Cardenas, MD (713-794-4404, NJCardenas@mdanderson.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Numeric Rating Scale Questionnaire (time frame: Through study completion; an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.